Jim Simons
HCWB icon

Jim Simons’s HCW Biologics HCWB Stock Holding History

Jim Simons’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-63
Closed -$6.69K – 3605
2024
Q4 		$6.69K Buy
+63
New +$7.35K ﹤0.01% 3529
2022
Q1 		– Sell
-50
Closed -$28K – 4224
2021
Q4 		$28K Buy
+50
New +$34K ﹤0.01% 3826

Other funds holding HCWB

APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
PIM
Pullen Investment Management Bradenton, Florida $216M AUM 32.94% 1-Year Est. Return
JWCA
J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $21.5B AUM 26.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Jim Simons's HCWB Position: Q1 2025 in Review

Jim Simons sold out of HCW Biologics (HCWB) in Q1 2025, closing a stake of 63 shares — an estimated $6.69K sold.

Jim Simons first reported a position in HCWB in Q4 2021 and held it in 2 quarters. The position peaked at $28K in Q4 2021. 14 funds tracked by Wall St. Rank hold HCWB as of Q1 2025.

  • Jim Simons reported no remaining HCW Biologics position as of Q1 2025 after selling out during the quarter.
  • Jim Simons sold 63 HCW Biologics shares in Q1 2025, an estimated $6.69K.
  • Jim Simons first reported a position in HCW Biologics in Q4 2021 and held it in 2 quarters.
  • Jim Simons's HCW Biologics position peaked at $28K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.